多肽CRDMO平台
目录肽
大奖888生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
THRO-005A
RGD-4C
Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly (Disulfide bridge: 2-10 and 4-8)
Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly (Disulfide bridge: 2-10 and 4-8)
Size：1
P1(RMB)：1070
MW：1145.3
One letter sequence：ACDCRGDCFCG (Disulfide bridge: 2-10 and 4-8)
Molecular Formula：C42H60N14O16S4
Description： This peptide, a double cyclic peptide, binds preferentially to integrins at sites of tumor angiogenesis and inflammed synovium in-vivo, and can be internalized into targeted cells.\n RGD-4C is a double cyclic peptide that can bind preferentially to integrins at sites of tumor angiogenesis and inflamed synovium in vivo, and can be internalized into targeted cells. Novel applications include the coupling of RGD-4C to proapoptotic domains to treat tumors and inflammatory arthritis, and to radioactive labels for the broad spectrum imaging of tumor tissue.
Literature Reference：Curnis, F. et al. Cancer Res. 64, 565 (2004)\nSu, Z. et al. Bioconjug. Chem. 13, 561 (2002)\nGerlag, M. et al. Arthritis Res. 3, 357 (2001)\nEllerby, H. et al. Nature Med. 5, 1032 (1999);
Cas：
P1(RMB)：1070
MW：1145.3
One letter sequence：ACDCRGDCFCG (Disulfide bridge: 2-10 and 4-8)
Molecular Formula：C42H60N14O16S4
Description： This peptide, a double cyclic peptide, binds preferentially to integrins at sites of tumor angiogenesis and inflammed synovium in-vivo, and can be internalized into targeted cells.\n RGD-4C is a double cyclic peptide that can bind preferentially to integrins at sites of tumor angiogenesis and inflamed synovium in vivo, and can be internalized into targeted cells. Novel applications include the coupling of RGD-4C to proapoptotic domains to treat tumors and inflammatory arthritis, and to radioactive labels for the broad spectrum imaging of tumor tissue.
Literature Reference：Curnis, F. et al. Cancer Res. 64, 565 (2004)\nSu, Z. et al. Bioconjug. Chem. 13, 561 (2002)\nGerlag, M. et al. Arthritis Res. 3, 357 (2001)\nEllerby, H. et al. Nature Med. 5, 1032 (1999);
Cas：
